Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemolizumab in prurigo nodularis long-term extension
NCT04204616Phase 3Active, not recruiting
- Sponsor
- Galderma
- Start
- Jan 2021
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
Phase 3, open-label, single-arm trial of nemolizumab in prurigo nodularis (PN), sponsored by Galderma. Primary endpoint: Adverse Events at 192 weeks. Started Jan 2021; status: active, not recruiting.
02
Drugs
nemolizumab
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on NCT04204616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04204616.